United Nations & Gilead Sciences

United Nations: Released $60 million for response; coordinating humanitarian aid and peacekeeping support.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.

United Nations: The United Nations>>> has mobilized emergency support and released funds to accelerate the Ebola response in the Democratic Republic of the Congo>>> and the region, providing logistical assistance and aid.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

United Nations: The United Nations released $60 million from its Central Emergency Response Fund to accelerate the Ebola response in the Democratic Republic of the Congo and the region.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

United Nations: The United Nations humanitarian office reported that almost a million people have been displaced from their homes by conflict in Democratic Republic of the Congo — Ituri Province, contributing to the challenges of the Ebola response.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

United Nations: Expressed concern over escalating violence affecting Ebola response.

Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.